Page 20 - ஜெநெடிக் திரையிடல் சோதனை க்கு ப்ரோவாக்டிவ் ஆரோக்கியம் மேலாண்மை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜெநெடிக் திரையிடல் சோதனை க்கு ப்ரோவாக்டிவ் ஆரோக்கியம் மேலாண்மை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜெநெடிக் திரையிடல் சோதனை க்கு ப்ரோவாக்டிவ் ஆரோக்கியம் மேலாண்மை Today - Breaking & Trending Today

New Clock Can Measure Biological Age Precisely

New Clock Can Measure Biological Age Precisely
by Anjanee Sharma on
March 4, 2021 at 3:43 PM
The BiT age (binarized transcriptomic aging clock) was developed by David Meyer and Professor Dr. Björn Schumacher.
Biological age differs substantially for everyone. Aging clocks like Horvath s epigenetic clock have been based on the pattern of methylations until now. These patterns are small chemical groups that attach to DNA and change with age.
The BiT age clock takes the set of genes read from DNA to make proteins for the cell into account.
Earlier the transcriptome was considered too complex to indicate age as sometimes genes transcribe a large amount of mRNA and sometimes less. So it was impossible to develop precise aging clocks based on gene activity. ....

David Meyer , Biological Age , Epigenetic Clock , டேவிட் மேயர் , உயிரியல் வாழ்நாள் , எபிஜெனெடிக் கடிகாரம் ,

Researchers develop a genetic patch to prevent hereditary deafness

They can hear well up to about forty years old, but then suddenly deafness strikes people with DFNA9. The cells of the inner ear can no longer reverse the damage caused by a genetic defect in their DNA. ....

Van Wijk , Erwin Van Wijk , Emily Henderson , Southern Netherlands , Molecular Therapy , வேன் விஜக் , அர்‌விந் வேன் விஜக் , எமிலி ஹென்டர்சன் , தெற்கு நெதர்லாந்து , மூலக்கூறு சிகிச்சை ,

Combination of therapies may benefit patients with mitochondrial respiratory chain disorders

Combination of therapies may benefit patients with mitochondrial respiratory chain disorders
Researchers from the Mitochondrial Medicine Frontier Program at Children s Hospital of Philadelphia (CHOP) have demonstrated how one combination of therapies may be beneficial for patients with mitochondrial respiratory chain disorders.
This preclinical research paves the way to develop more tailored treatment options for patients with inherited mitochondrial disease and acquired energy disorders. The findings emphasize the importance of rational therapeutic modeling to target specific cellular deficiencies and provide proper cellular nutrition as an effective means to manage mitochondrial disease.
The findings were published online by the journal
Human Molecular Genetics. ....

United States , Sujay Guha , Marni Falk , Neald Mathew , Emily Henderson , Division Of Human Genetics , Mitochondrial Medicine Frontier Program , Human Molecular , Study Senior Author , Human Genetics , Attending Physician , Executive Director , Mitochondrial Medicine , Mitochondrial Disease , Metabolic Disorders , ஒன்றுபட்டது மாநிலங்களில் , சுஜய் குஹா , மார்னி ஃபாக் , எமிலி ஹென்டர்சன் , பிரிவு ஆஃப் மனிதன் ஜெநெடிக்ஸ் , மைட்டோகாண்ட்ரியல் மருந்து எல்லை ப்ரோக்ர்யாம் , மனிதன் மூலக்கூறு , படிப்பு மூத்தவர் நூலாசிரியர் , மனிதன் ஜெநெடிக்ஸ் , கலந்துகொள்வது மருத்துவர் , நிர்வாகி இயக்குனர் ,

Researchers develop mutant gene-targeted immunotherapy approach to fight cancers

Researchers develop mutant gene-targeted immunotherapy approach to fight cancers
A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center employs new antibodies against genetically altered proteins to target cancers.
The researchers targeted their immunotherapy approach to alterations in the common cancer-related p53 tumor suppressor gene, the RAS tumor-promoting oncogene or T-cell receptor genes. They also tested the therapy on cancer cells in the laboratory and in animal tumor models. Their findings are reported in three related studies published March 1 in
Science Immunology, ....

Emily Han , Emily Henderson , Bert Vogelstein , Suman Paul , Kenneth Kinzler , Katharine Wright , Alex Pearlman , Jacqueline Douglass , Sandra Gabelli , Johns Hopkins , Chung Hsiue , Bloomberg Kimmel Institute For Cancer Immunotherapy , Johns Hopkins Kimmel Cancer Center , Ludwig Center , Experimental Therapeutics For The Ludwig Center , Johns Hopkins University School Of Medicine , Howard Hughes Medical Institute , Lustgarten Laboratory , Kimmel Institute , Science Immunology , Science Translational , Johns Hopkins University School , Emily Han Chung Hsiue , Johns Hopkins Report , Senior Author , Associate Professor ,

Lung cancer cells activate different signaling pathways in response to KRAS inhibitors

Lung cancer cells activate different signaling pathways in response to KRAS inhibitors
Genetic alterations of the KRAS gene are some of the most common mutations in lung cancer patients, but unfortunately these patients have few effective treatment options. Drugs that target the G12C mutation in KRAS have shown some activity in lung cancer; however, alternative signaling pathways are often activated that bypass the KRAS inhibitor, resulting in drug resistance.
In a new article published in
Clinical Cancer Research, Moffitt Cancer Center researchers show that various subtypes of lung cancer cells activate different signaling pathways in response to KRASG12C inhibitor treatment. These results may help identify potential combination therapy approaches and guide treatment decisions for lung cancer patients in the future. ....

Emily Henderson , Moffitt Cancer Center , Clinical Cancer Research , Lung Cancer , Adeno Carcinomas , Cell Line , எமிலி ஹென்டர்சன் , மாஃபிட் புற்றுநோய் மையம் , மருத்துவ புற்றுநோய் ஆராய்ச்சி , நுரையீரல் புற்றுநோய் , செல் வரி ,